MAS1L and Parkinson disease: The ACE1/AngII-AT1R pathway has detrimental effects [4] including stimulating an oxidative environment and leading to inflammation, vasoconstriction and apoptosis [18,38], whereas the non-classical pathways ACE2/Ang(1-7)-MasR and Ang II/AT2R have beneficial effects against neurodegeneration, as seen in PD or AD [4], including reducing oxidative and inflammatory levels, promoting vasodilation and inactivating proliferative processes [18].